Jiangsu Xuantai Pharmaceutical Co., Ltd

Primary Research Objectives Part A: To evaluate the safety and tolerability of a single oral dose of FH001 tablets in healthy subjects. Part B: To evaluate the effect of food on the pharmacokinetic (PK) characteristics of a single oral dose of FH001 tablets in healthy subjects. Part C: To evaluate the safety and tolerability of multiple oral doses of FH001 tablets in healthy subjects. Secondary Research Objectives Part A: To evaluate the PK characteristics of a single oral dose of FH001 tablets in healthy subjects; To evaluate the effect of different single oral doses of FH001 tablets on the QT interval in healthy subjects. Part B: To evaluate the safety and tolerability of a single oral dose of FH001 tablets in healthy subjects under fasting and postprandial conditions. Part C: To evaluate the PK characteristics of single and multiple oral doses of FH001 tablets in healthy subjects; To evaluate the effect of different single and multiple oral doses of FH001 tablets on the QT interval in healthy subjects. Exploratory Objectives Part A: To evaluate the pharmacodynamic characteristics of a single oral dose of FH001 tablets in healthy subjects. Part C: Evaluate the urinary pharmacokinetic characteristics of healthy subjects after multiple oral administrations of FH001 tablets. Identify the metabolites of FH001 at selected doses, if data permit.

Primary objective: To evaluate the effect of a low-fat meal on the pharmacokinetics of gumetinib tablets after oral administration in healthy participants. Secondary objectives: To assess the pharmacokinetic characteristics of gumetinib tablets after oral administration in healthy participants under fasting and low-fat meal conditions; and to assess the safety and tolerability of gumetinib tablets after oral administration in healthy participants under fasting and low-fat meal conditions.

Primary objective: To investigate the pharmacokinetic characteristics of a single oral dose of the test formulation, Lebrexone tablets (5 mg, manufactured by Jiangsu Xuantai Pharmaceutical Co., Ltd.), and the reference formulation, Lebrexone tablets (Dayvigo®, 5 mg; manufactured by EISAI MANUFACTURING Ltd.), in healthy participants under fasting conditions, and to evaluate the bioequivalence of the two formulations under fasting oral administration. Secondary objective: To investigate the safety of the test formulation, Lebrexone tablets (5 mg), and the reference formulation, Lebrexone tablets (Dayvigo®) (5 mg), in healthy participants.